EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer

Michael R Mallmann iD, Sina Tamir, Katharina Alfter, Dominik Ratiu, Alexander Quaas iD, Christian M Domroese iD

Cancers · 06.05.2024 · 16 (9) · 1787

DOI: 10.3390/cancers16091787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 06.05.2024. Verfasst von Michael R Mallmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Cologne, 50931 Cologne, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

There is a huge unmet clinical need for novel treatment strategies in advanced and recurrent cervical cancer. Several cell membrane-bound molecules are up-regulated in cancer cells as compared to normal tissue and have revived interest with the introduction of antibody–drug conjugates (ADCs). (2)

Methods

In this study, we characterize the expression of 10 potential ADC targets, TROP2, mesotheline, CEACAM5, DLL3, folate receptor alpha, guanylatcyclase, glycoprotein NMB, CD56, CD70 and CD138, on the gene expression level. Of these, the three ADC targets TROP2, CEACAM5 and CD138 were further analyzed on the protein level. (3)

Results

TROP2 shows expression in 98.5% (66/67) of cervical cancer samples. CEACAM5 shows a stable gene expression profile and overall, 68.7% (46/67) of cervical cancer samples are CEACAM-positive with 34.3% (23/67) of cervical cancer samples showing at least moderate or high expression. Overall, 73.1% (49/67) of cervical cancer samples are CD138-positive with 38.8% (26/67) of cervical cancer samples showing at least moderate or high expression. (4)

Conclusions

TROP2, CEACAM5 or CD138 do seem suitable for further clinical research and the data presented here might be used to guide further clinical trials with ADCs in advanced and recurrent cervical cancer patients.

Schlagwörter

Stichwörter der Autor:innen

CD138CEACAM5TROP2antibody–drug conjugatescervical cancer

Autor:innen und Institutionen

  • Faculty of Medicine, University of Cologne, 50931 Cologne, Germany.
  • Department of Obstetrics and Gynecology, University of Cologne, 50931 Cologne, Germany.
  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Germany.
  • Department of Obstetrics and Gynecology, Hospital of the City of Cologne, 51069 Cologne, Germany.
  • Department of Pathology, University of Cologne, 50931 Cologne, Germany.

ORCID-Profile: Michael R Mallmann, Alexander Quaas, Christian M Domroese

Zitieren

APA

Mallmann, M. R., Tamir, S., Alfter, K., Ratiu, D., Quaas, A., & Domroese, C. M. (2024). Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer. Cancers, 16(9), 1787. https://doi.org/10.3390/cancers16091787

Vancouver

Mallmann MR, Tamir S, Alfter K, Ratiu D, Quaas A, Domroese CM. Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer. Cancers. 2024;16(9):1787. doi:10.3390/cancers16091787

BibTeX
@article{Mallmann2024,
  author = {Mallmann, Michael R and Tamir, Sina and Alfter, Katharina and Ratiu, Dominik and Quaas, Alexander and Domroese, Christian M},
  title = {Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1787},
  doi = {10.3390/cancers16091787}
}
Kostenlos starten →